ALLMedicine™ Radical Prostatectomy Center
Research & Reviews 6,281 results
https://clinicaltrials.gov/ct2/show/NCT04808427
Jan 27th, 2023 - Background: Prostate cancer is relatively slow growing, with doubling times for local tumors estimated at 2 to 4 years. Some prostate cancers prove to be small, low grade, and noninvasive and they appear to pose little risk to the life or health o...
https://clinicaltrials.gov/ct2/show/NCT02933255
Jan 27th, 2023 - Background: Immune checkpoint inhibitors interfere with the immune system s autoregulatory mechanisms, allowing for a potentially expanded and prolonged T-cell response with the possibility of greater antitumor effects. Nivolumab is a fully human ...
https://clinicaltrials.gov/ct2/show/NCT03456843
Jan 26th, 2023 - PRIMARY OBJECTIVES: I. To assess the clinical benefit of combining radical surgery cytoreductive radical prostatectomy (CRP) - with the best systemic therapy (BST) in men with newly diagnosed clinical metastatic prostate cancer (mPCa). SECONDARY O...
https://clinicaltrials.gov/ct2/show/NCT03860987
Jan 26th, 2023 - Background: Most men diagnosed with prostate cancer will present with intermediate or high-risk disease, and many develop castrate resistant prostate cancer (CRPC) as curative strategies are often unsuccessful Treatment options typically involve r...
https://clinicaltrials.gov/ct2/show/NCT04219059
Jan 26th, 2023 - Quantitative approaches to medical image analysis have been developed in recent years with the aim to overcome the limitation of qualitative image interpretation, and provide biomarkers for disease characterization. In particular, the new paradigm...
Guidelines 8 results
https://doi.org/10.1016/j.ijrobp.2020.11.010
International Journal of Radiation Oncology, Biology, Phy... Robin S, Jolicoeur M et. al.
Nov 14th, 2020 - Prostate bed (PB) irradiation is considered the standard postoperative treatment after radical prostatectomy (RP) for tumors with high-risk features or persistent prostate-specific antigen, or for salvage treatment in case of biological relapse. F...
https://doi.org/10.5858/arpa.2020-0015-RA
Archives of Pathology & Laboratory Medicine; Epstein JI, Amin MB et. al.
Jun 27th, 2020 - Controversies and uncertainty persist in prostate cancer grading. To update grading recommendations. Critical review of the literature along with pathology and clinician surveys. Percent Gleason pattern 4 (%GP4) is as follows: (1) report %GP4 in n...
https://doi.org/10.1016/j.jacr.2018.03.019
Journal of the American College of Radiology : JACR; , Froemming AT et. al.
May 5th, 2018 - Diagnosis and management of prostate cancer post treatment is a large and complex problem, and care of these patients requires multidisciplinary involvement of imaging, medical, and surgical specialties. Imaging capabilities for evaluation of men ...
https://doi.org/10.1200/JCO.2016.72.0466
Journal of Clinical Oncology : Official Journal of the Am... Chin J, Rumble RB et. al.
Mar 28th, 2017 - Purpose To jointly update the Cancer Care Ontario guideline on brachytherapy for patients with prostate cancer to account for new evidence. Methods An Update Panel conducted a targeted systematic literature review and identified more recent random...
https://doi.org/10.1016/j.jsxm.2016.11.324
The Journal of Sexual Medicine; Salonia A, Adaikan G et. al.
Mar 7th, 2017 - Sexual dysfunction is common in patients after radical prostatectomy (RP) for prostate cancer. To provide the International Consultation for Sexual Medicine (ICSM) 2015 recommendations concerning management strategies for post-RP erectile function...
Clinicaltrials.gov 770 results
https://clinicaltrials.gov/ct2/show/NCT04808427
Jan 27th, 2023 - Background: Prostate cancer is relatively slow growing, with doubling times for local tumors estimated at 2 to 4 years. Some prostate cancers prove to be small, low grade, and noninvasive and they appear to pose little risk to the life or health o...
https://clinicaltrials.gov/ct2/show/NCT02933255
Jan 27th, 2023 - Background: Immune checkpoint inhibitors interfere with the immune system s autoregulatory mechanisms, allowing for a potentially expanded and prolonged T-cell response with the possibility of greater antitumor effects. Nivolumab is a fully human ...
https://clinicaltrials.gov/ct2/show/NCT03456843
Jan 26th, 2023 - PRIMARY OBJECTIVES: I. To assess the clinical benefit of combining radical surgery cytoreductive radical prostatectomy (CRP) - with the best systemic therapy (BST) in men with newly diagnosed clinical metastatic prostate cancer (mPCa). SECONDARY O...
https://clinicaltrials.gov/ct2/show/NCT03860987
Jan 26th, 2023 - Background: Most men diagnosed with prostate cancer will present with intermediate or high-risk disease, and many develop castrate resistant prostate cancer (CRPC) as curative strategies are often unsuccessful Treatment options typically involve r...
https://clinicaltrials.gov/ct2/show/NCT04219059
Jan 26th, 2023 - Quantitative approaches to medical image analysis have been developed in recent years with the aim to overcome the limitation of qualitative image interpretation, and provide biomarkers for disease characterization. In particular, the new paradigm...
News 759 results
https://www.medpagetoday.com/hematologyoncology/cervicalcancer/102634
Jan 13th, 2023 - A California study showed a concerning increase in cervical cancer mortality among women 65 or older, the age at which routine screening is no longer recommended. (UC Davis Comprehensive Cancer Center, Cancer Epidemiology, Biomarkers & Prevention)...
https://www.medpagetoday.com/hematologyoncology/prostatecancer/102117
Dec 7th, 2022 - Excluding systematic biopsy in favor of MRI-targeted biopsy in men with elevated prostate-specific antigen (PSA) levels reduced the probability of detecting clinically insignificant cancers, but at the risk of missing some clinically significant c...
https://www.onclive.com/view/investigators-highlight-top-advances-at-esmo-2022
Nov 7th, 2022 - Lung, Head and Neck Cancers Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study (Abstract LBA 10) The KRAS G12C inhibitor sotorasib (Lumakras) doubled the rate of...
https://www.onclive.com/view/dr-aggarwal-on-adt-intensification-in-biochemically-relapsed-prostate-cancer
Oct 20th, 2022 - Rahul Aggarwal, MD, developmental therapeutics specialist, genitourinary oncologist, the University of California Health (UCSF), UCSF Helen Diller Family Comprehensive Cancer Center, discusses the rationale for investigating androgen deprivation t...
https://www.onclive.com/view/two-years-post-operative-adt-plus-radiotherapy-improves-mfs-time-to-salvage-therapy-in-prostate-cancer
Sep 26th, 2022 - The addition of 24 months of androgen deprivation therapy (ADT) to postoperative radiotherapy after radical prostatectomy provided a metastasis-free survival (MFS) benefit and improved time to salvage therapy in patients with prostate cancer, acco...